QUICK SNAPSHOT

DSIP

Sleep & Neuromodulation

Regulatory · Apr 2026 Under PCAC review July 23-24, 2026 for possible §503A Bulks List inclusion. Read more →
FDA Status
Not FDA-Approved
Claimed Benefits
  • Sleep regulation (mixed evidence)
  • Chronic pain reduction (pilot)
  • Neuroendocrine modulation
Clinical Evidence
4
Human Trials
Phase II
Highest Phase

A rigorous 1992 double-blind trial concluded DSIP's sleep effects were weak and likely placebo-driven.

Read Full Deep Dive

Mechanism, dosing, vendor pricing, and full research citations

The Peptide Digest

Stay ahead of the market

New peptide profiles, vendor pricing shifts, and research updates. No spam, unsubscribe anytime.